Pharmacoeconomics have been used in various ways, including at the institutional level and for formulary decision-making around specialty pharmaceuticals. This program reviews the role of pharmacoeconomics and cost-effectiveness thresholds, along with mechanisms that influence and affect drug policy listing decisions.
This program is supported by Pharmascience
Ahmad Abulaban, MBBS, SBN, CRND, MSCS, ABCN (CCEEG)
Assistant Professor of Neurology
King Saud bin-Abdulaziz University for Health Sciences
Neurology Consultant
Division of Neurology, Department of Medicine
King Abdulaziz Medical City, National Guard Health Affairs
Yaser M. Al Malik, MD, FRCPC, American Board of Psychiatry and Neurology, CSCN (EEG & EMG)
Assistant professor and Consultant Neurologist
King Saud bin Abdulaziz University for Health Sciences
King Abdulaziz Medical City, Ministry of National Guard Health Affairs
Moe Abdallah, B.SC., B.SC.PHM., R.PH
Clinical pharmacist, Drug Programs Policy and Strategy Branch
Ontario Public Drug Programs
Ministry of Health and Long-Term Care
Michael Boivin, RPh, BScPhm
Clinical Pharmacist Consultant and Continuing Education Developer
This continuing education lesson is designed primarily for pharmacists and has been accredited by the Canadian Council on Continuing Education in Pharmacy (CCCEP) for 0.5 CEUs.
CCCEP File Number: 1066-2022-3381-I-P.
After viewing this expert brief, participants will be better able to: